Purpose To evaluate differences in clinical, radiological and laboratory findings between pulmonary metastasis with and without radioiodine avidity in thyroidectomized differentiated thyroid cancer (DTC) patients with pulmonary metastasis who underwent high-dose I-131 treatment. Methods A total of 105 DTC patients with pulmonary metastasis (age, 48.7±16.8 years; women/men, 78/27) were included. Clinical characteristics, chest computed tomography (CT), F-18 fluorodeoxyglucose positron emission tomography (F-18 FDG PET)/CT and thyroid-stimulating hormone (TSH)-stimulated serum thyroglobulin (s-Tg) level were compared between patients with and without radioiodine uptake in metastatic lung lesions. The response to I-131 treatment was evaluated with follow-up study. Results Eighty-nine patients (84.8 %, whole-body scan positive [WBSP] group) showed radioiodine uptake at pulmonary metastasis on post I-131 treatment whole-body scan (WBS) and 16 patients (15.2 %, WBS negative [WBSN] group) did not show uptake at pulmonary lesions on the WBS. Ninety percent and 87 % of the WBSP group had visible metastatic lesions on CT and F-18 FDG PET/CT; however, all of the patients in the WBSN group showed lesions on CT and F-18 FDG PET/CT. In seven (6.7 %) of 105 patients, CT and F-18 FDG PET/CT could not detect pulmonary lesions, which were diagnosed by post I-131 treatment WBS. Complete disease remission was achieved in six (5.7 %) patients and all of them were in the WBSP group. Conclusions Metastatic lesion was not visualized on chest CT or F-18 FDG PET/CT in 6.7 % of DTC patients with pulmonary metastasis and the lesion was visualized only on post I-131 treatment WBS. Complete remission was achieved in 5.7 % of DTC patients with pulmonary metastasis and the cured metastases were non-visualizing or micronodular lesions on chest CT and demonstrated radioiodine avidity on post I-131 treatment WBS.
Introduction
Thyroid cancer accounts for 90 % of all endocrine malignancies [1] . Incidence has been suggested to show an increase in recent years [2] . Differentiated thyroid cancer (DTC) constitutes more than 90 % of all thyroid cancer [3] . Total thyroidectomy, radioiodine ablation, and TSH suppression are the most common methods used in treatment of DTC. Although the prognosis of DTC is usually good, recurrences and metastases may develop in the coming years. Approximately 10-15 % of patients with DTC present with or subsequently develop distant metastases. In this group of patients, the 10-year disease-specific survival rate drops to 40 % [4] . The lungs are the most frequent distant localization of metastases from DTC and its incidence had been reported to be variable, up to 7 % [5] [6] [7] . The ratio of complete response of pulmonary metastasis to I-131 treatment is not very high, therefore, metastasis is known as a poor prognostic factor [4, 5] .
Despite the prognostic importance of pulmonary metastasis, it may not be visualized on plain chest radiography [8] . Accurate diagnosis and appropriate management of metastasis can improve the clinical outcome and radioiodine avidity of the metastasis is a crucial factor in tailoring of a therapeutic plan; however, relatively little information regarding the clinical, radiological, and laboratory findings of pulmonary metastasis according to radioiodine avidity has been reported in previous literature.
In the current study, we aimed to evaluate the difference in clinicoradiological findings of pulmonary metastasis according to radioiodine avidity in DTC patients.
Patients and Methods

Patients
A waiver of institutional review board approval was obtained for this retrospective analysis. A total of 3,844 thyroidectomized DTC patients who underwent high-dose I-131 ablation/ treatment at the Department of Nuclear Medicine, Kyungpook National University Hospital for a 12-year period from January 2000 to December 2011 were reviewed retrospectively. Post I-131 treatment whole-body scan (WBS), thyroidstimulating hormone (TSH)-stimulated serum thyroglobulin (s-Tg) levels were obtained, and, when necessary, other chest imaging studies (chest computed tomography [CT], F-18 fluorodeoxyglucose positron emission tomography [F-18 FDG PET]/CT) were performed for evaluation of pulmonary metastasis. Pulmonary metastasis was diagnosed when lung lesion was histologically proven as thyroid cancer, or when lung lesions shows tracer accumulation on diagnostic or therapeutic I-131 WBS, or when metastatic lesions were visualized on other imaging studies (chest CT, F-18 FDG PET/CT) and TSH-stimulated s-Tg>2 ng/ml. Among these patients, 105 patients had pulmonary metastases.
Patients were divided into two groups based on the radioiodine avidity of the pulmonary metastases on the post I-131 treatment WBS. The WBS-positive (WBSP) group included patients with radioiodine avid pulmonary metastasis on the WBS. The WBS-negative (WBSN) group included patients with non-radioiodine avid pulmonary metastasis on the WBS. The following prognostic variables were compared between the two groups: age at diagnosis, sex, histological type, local tumor extension, cervical lymph node involvement, and presence of metastases in distant sites other than lungs, TSH-stimulated s-Tg, chest CT, and F-18 FDG PET/CT.
I-131 Treatment and Post I-131 Treatment WBS
Four weeks before administration of I-131, levothyroxine replacement treatment was withdrawn and a low iodine diet protocol was applied for the last 2 weeks [9] . TSH levels were increased to at least 30 uIU/ml in each patient. Each patient received 5.1-7.4 GBq (150-200 mCi) I-131. I-131 treatment was repeated periodically (at least 6-month intervals) for patients with persistent radioiodine avid pulmonary metastases.
For post I-131 treatment WBS, a dual-headed gamma camera equipped with a high-resolution collimator (Infinia II; GE, Milwaukee, WI, USA) was used. Images of anterior and posterior projection were obtained from the 5th to 7th days after I-131 administration using a matrix size of 512× 512. Spot images were also acquired when indicated.
Chest CT
Chest CT was performed only when pulmonary metastases were detected by positive I-131 WBS and/or increasing s-Tg levels. All chest CT scans were performed using a 16-channel multi-detector-row helical CT scanner (Lightspeed 16; GE Healthcare, Milwaukee, WI, USA). CT images were obtained using a 2.5-mm or a 5-mm slice thickness, starting from the apex of the lungs to the lung base. All CT images were obtained with the patient in the supine position. Patients were evaluated in terms of metastatic pulmonary lesions and the lesions were classified according to size: larger than 10 mm was defined as a macronodule and smaller than 10 mm was defined as a micronodule.
F-18 FDG PET/CT Acquisition Protocol
All patients fasted for at least 6 h, and blood glucose levels were checked before administration of F-18 FDG. Patients with elevated blood glucose levels had their examinations rescheduled and blood glucose concentration was managed to be less than 150 mg/dl in all subjects. Approximately 8.1 MBq of F-18 FDG per kilogram of body weight was administered by intravenous injection, and patients were advised to rest for 1 h before acquisition of the PET/CT image. PET/CT scans were performed using a Reveal RT-HiREZ sixslice CT apparatus (CTI Molecular Imaging, Knoxville, TN, USA) and a 16-slice CT Discovery STE apparatus (GE Healthcare, Milwaukee, WI, USA). Before the PET scan, for attenuation correction, a low-dose CT scan was obtained without contrast enhancement from the skull base to the thigh, with the patient supine and breathing quietly. PET scans with a maximum spatial resolution of 6.5 mm (Reveal PET/CT) and 5.5 mm (Discovery PET/CT) were also obtained from the skull base to the thigh, at 3 min per bed position. PET images obtained using the Reveal PET/CT and Discovery PET/CT scanners were reconstructed with a 128×128 matrix, an ordered-subset expectation maximum iterative reconstruction algorithm (four iterations, eight subsets), a Gaussian filter of 5.0 mm, and a slice thickness of either 3.0 mm (Reveal PET/ CT) or 3.27 mm (Discovery PET/CT).
Serum Thyroglobulin Measurement
TSH stimulated s-Tg was obtained prior to administration of I-131 using a radioimmunoassay commercial kit (Thyroglobulin-IRMA; CIS Bio International, France). Patients were classified into two groups according to s-Tg levels; s-Tg<450 ng/ml; s-Tg≥450 ng/ml.
Therapeutic Approach and Follow-up Schedule
The mean follow-up period was 71.0 months (up to 309 months). Patients with persistent pulmonary metastasis which demonstrated radioiodine avidity underwent additional I-131 treatments at least annually until complete remission is achieved or the metastatic lesions lose radioiodine avidity. The number of I-131 treatments ranged from 1 to 9 times, mean 3.1 times. The cumulative dose of treatment ranged from 150 mCi to 1,800 mCi, mean 587.4 mCi. Complete remission of the metastasis was defined as negative diagnostic or post I-131 treatment WBS, normal chest CT, and TSH stimulated sTg levels less than 2 ng/ml.
Statistical Analyses
Continuous data were expressed as mean±standard deviation; categorical data were presented as frequency and percentage. Continuous data analysis was performed using independent samples t -test and categorical data were calculated using Pearson's chi-square test. Medcalc software (Windows XP, version 12.3, Broekstraat, Mariakerke, Belgium) was used in performance of statistical analysis. A P value of less than 0.05 was considered statistically significant.
Results
Patients' Characteristics
Our cohort consisted of 27 men (25.7 %) and 78 women (74.3 %). The age of the subjects was 48.7±16.8 years, ranging from 11 years to 76 years of age. Eighty-nine patients (84.8 %, WBSP group) showed radioiodine uptake on post I-131 treatment WBS and 16 patients (15.2 %, WBSN group) did not show uptake at pulmonary lesions on the WBS. A papillary carcinoma was diagnosed in 88 patients, and a follicular carcinoma in 17 patients. Sixty-two out of 105 patients had pulmonary metastasis before the first I-131 treatment and the other 46 patients developed pulmonary metastasis during the follow-up period. The lungs were the sole distant metastatic lesion in 88 patients (83.8 %), while 17 patients (16.2 %) also had concomitant metastases to bones (16 patients) or to the liver (one patient).
Subjects in the WBSP group were younger than those in the WBSN group (mean age, 46.8±16.9 vs 59.4±11.9, P = 0.0053). However, there were no statistically significant differences in sex, histopathologic type, T and N stages, and additional distant metastases other than the lungs between the WBSP and the WBSN groups. The patients' clinical and histopathologic characteristics are shown in Tables 1 and 2. Post I-131 Treatment WBS vs Chest CT Forty-one patients underwent Chest CT before I-131 treatment and 38 (92.7 %) patients showed lung nodules on the chest CT. In the WBSP group, 90.3 % (28/31) of patients showed lung nodules on the chest CT. Among the 28 patients, 11 patients had macronodules and 17 patients had micronodules. On the contrary, in the WBSN group, all ten patients who underwent CT scan before I-131 treatment WBSP whole-body scan positive, WBSN whole-body scan negative showed lung nodules on the chest CT and only one patient had macronodules and nine patients showed micronodules (Fig. 1) .
Post I-131 Treatment WBS vs F-18 FDG PET/CT
Pulmonary metastasis was discerned in 36 patients who underwent F-18 FDG PET/CT before I-131 treatment. Thirty-three patients showed lung nodules on F-18 FDG PET/CT. In the WBSP group, 20 of 23 patients showed lung nodules on F-18 FDG PET/CT. Only 12 patients had an FDG uptake in metastatic pulmonary nodules, eight patients showed metastatic pulmonary nodules without an FDG uptake (Fig. 2) . Three patients did not show metastatic pulmonary nodules (Fig. 3) . In the WBSN group, 13 patients underwent F-18 FDG PET/CT. Eight patients had an FDG uptake at metastatic pulmonary nodules and the other five patients showed metastatic pulmonary nodules without an FDG uptake. However, no statistical difference of FDG uptake at the pulmonary nodule was observed between the WBSP and the WBSN groups. 
Patients with Lung Metastases
TSH-Stimulated s-Tg vs Radioiodine Avidity of Pulmonary Metastasis
Thirty-one (34.8 %) of the 89 patients of the WBSP group had a TSH stimulated s-Tg level higher than 450 ng/ml and only three (18.8 %) among 16 patients of WBSN group had TSHstimulated s-Tg levels higher than 450 ng/ml. Although WBSP group showed a higher incidence of having high Table 3 .
Patterns of I-131 Uptake on Post I-131 Treatment WBS
Among 89 patients in the WBSP group, 35 patients had a diffuse uptake pattern and 54 patients had a focal uptake pattern (nine patients with single focal uptake and 45 patients with multiple focal uptakes). Table 4 shows the patterns of I-131 uptake on post I-131 treatment WBS.
Response to I-131 Treatment
Among all 105 subjects, clinical data on therapeutic response were obtained for 78 patients. Complete remission was achieved in six (5.7 %) patients. All six patients belonged to the WBSP group; therefore, complete remission rate by treatment with I-131 was 9.1 % in the WBSP group (Table 5 ). Characteristics of all six patients who achieved complete remission by I-131 treatment were as follows. All were women and mean age was 45.2±14.0 years. Histological subtype was only papillary carcinoma. All patients revealed obvious I-131 uptake on pulmonary metastatic lesions; however, five patients did not have pulmonary lesions on the chest CT and a patient had micronodular pulmonary metastases (lesser than 3 mm in diameter) on the chest CT. The TSH-stimulated s-Tg levels of the six patients were lower than 15 ng/ml. 
Discussion
The lungs are the most frequent distant localization of metastases from DTC, and the incidence of thyroid cancer with pulmonary metastasis has been reported as approximately 1.3-7 % [5] [6] [7] . In the current study, the incidence of pulmonary metastasis in DTC patients was found to be 2.7 %. In patients with pulmonary metastases from DTC, I-131 uptake by metastases is known to be the most important factor having a positive effect on prognosis [10] . In our study, pulmonary metastases were observed in 89 (84.8 %) patients on the post I-131 treatment WBS; however, 16 (15.2 %) patients did not show any abnormal uptake at the pulmonary metastasis on post I-131 treatment WBS. Among 78 patients from whom the author obtained clinical results, complete disease remission was achieved in six (5.7 %), all of whom belonged to the WBSP group. In the WBSN group, all patients were in persistent disease status. Sensitivity of chest CT for pulmonary metastasis of DTC has been reported as 82 % [11] . On the contrary, some studies have shown that a chest CT scan can detect only a small number of peripheral micronodules since the central micronodules remain undistinguishable from adjacent vessel structures [12] . In the current study, chest CT detected pulmonary metastases in 38/41 patients (92.7 %), its diagnostic sensitivity was higher than that of post I-131 treatment WBS. Although post I-131 treatment WBS has lower diagnostic sensitivity for pulmonary metastases of DTC compared with a chest CT, it has better specificity for the disease and is able to forecast the disease's response to I-131 treatment. In addition, it is sometimes the only imaging method showing pulmonary metastasis.
F-18 FDG PET can be useful for localizing distant metastases, especially when the metastases have no radioiodine avidity, such as poorly differentiated thyroid carcinoma. Several investigators have reported that F-18 FDG PET and I-131 WBS played complementary roles in detection of recurrent or metastatic DTC due to a flip-flop phenomenon [13] [14] [15] [16] . According to this phenomenon, DTC with good differentiation usually takes up radioiodine but does not take up FDG, whereas DTC with poor differentiation takes up FDG but does not take up radioiodine [13] [14] [15] [16] . In the current study, F-18 FDG PET/CT detected pulmonary metastases in 33/36 patients (91.7 %). A PET image found pulmonary metastases in 20/36 patients (55.6 %) and a CT image found pulmonary metastases in 33/36 patients (91.7 %). Patients having pulmonary metastasis with FDG uptake had larger nodule size than patients having pulmonary metastasis without FDG uptake. Although F-18 FDG PET/CT can provide anatomical and molecular information on glucose metabolism of pulmonary metastasis of DTC, the image cannot be used for prediction of therapeutic response to I-131.
The s-Tg level is the most sensitive and specific marker of persistent or recurrent disease in DTC patients; however, high s-Tg concentration alone is not enough for the diagnosis when there is a certain amount of remnant thyroid tissue. In the current study, among 105 patients, 69 (65.7 %) had a TSH stimulated s-Tg level higher than 60 ng/ml. In a study of DTC patients with metastases, Filesi et al. [17] reported that 66.7 % had TSH-stimulated s-Tg levels higher than 60 ng/ml. They also reported that metastases were observed in the initial post I-131 treatment WBS in 47.8 % of DTC patients with s-Tg levels less than 60 ng/ml. In their study, 61.3 % of patients showing a negative result on initial I-131 WBS had s-Tg levels higher than 60 ng/ml. In the current study, 69 (65.7 %) among 105 patients had a TSH-stimulated s-Tg level higher than 60 ng/ml, and 12 (63.2 %) among 19 patients having a negative result on post I-131 treatment WBS had an s-Tg level higher than 60 ng/ml.
In the current study, the patients were divided into two groups according to the TSH-stimulated s-Tg level: those with s-Tg levels higher than 450 ng/ml and those with s-Tg levels lower than 450 ng/ml. It is assumed that a well differentiated thyroid cancer lesion can take up radioiodine and also produce Tg. On the contrary, a thyroid cancer lesion with dedifferentiation might not be not able to take up radioiodine or to produce Tg. In the current study, the WBSP group showed a higher incidence of high TSH-stimulated s-Tg level (≥450) and the WBSN group showed a higher incidence of low TSHstimulated s-Tg level (≥450). This result supports relations between differentiation of metastasis and its biological characteristics of radioiodine avidity and Tg production.
Fortunately, unresectable distant metastases in DTC patients can be cured with I-131 treatment. Samuel et al. [4] reported that 30.8 % of DTC patients with pulmonary metastases can be cured, improvement can be achieved in 65.4 % with I-131 treatment, and only 3.8 % of patients do not respond to treatment. In a study of 394 DTC patients with pulmonary and/or bone metastases, Schlumberger et al. [18] WBSP whole body scan positive, WBSN whole body scan negative reported that two-thirds of the distant metastases showed radioiodine avidity and 46 % of subjects responded to I-131 treatment. In the current study, among 66 patients with radioiodine avid pulmonary metastases, complete disease remission was achieved in six (9.1 %). The prognosis of DTC patients with pulmonary metastasis was known to be related to the size of the metastasis. The reported 10-year survival rate is about 90 % in DTC patients with functioning pulmonary metastases and positive chest radiography, and the rate was approximately 78 % in the patients with functioning pulmonary metastases and negative chest radiography [19] . In addition, miliary metastases, which results in diffuse pulmonary uptake on post I-131 treatment WBS, appears to have a better prognosis than macronodular metastases, which results in nodular uptake on the post I-131 treatment WBS [20, 21] . The success rate of I-131 treatment can be higher in pulmonary micrometastases that cannot even be visualized on CT due to their infinitesimal size. The main reason for a high success rate in small size metastasis appears to be related to a short proceeding distance of β-particles of I-131 in tissue (0.08-2.3 mm) [22] . It is also important to recognize that the micronodular pulmonary metastases generally have good radioiodine uptake than macronodular metastases [6] . Results of the current study also showed that a complete response to I-131 treatment was 9 % (3/35) in diffuse tiny miliary pulmonary metastases, and 6 % (3/54) in nodular pulmonary metastases. Naturally, complete response was achieved only in the WBSP group, and the rate was 9.1 %. The authors assume that the rate will increase with additional I-131 treatments and long-term follow-up.
The limitations of our study include its retrospective nature and small sample size. In this study, survival statistics were not preformed. There was no significant survival difference by iodine or FDG uptake on the pulmonary metastatic lesion (data were not shown), probably due to a short follow-up period. Therefore, conduct of a larger, ideally prospective long-term follow-up study is needed in order to validate the results of the current study.
Conclusion
Metastatic lesion was not visualized on chest CT or F-18 FDG PET/CT in 6.7 % of DTC with pulmonary metastasis and the lesion was visualized only on post I-131 treatment WBS. Complete remission was achieved in 5.7 % of DTC with pulmonary metastasis and the cured metastases were nonvisualizing or micronodular lesions on chest CT and demonstrated radioiodine avidity on post I-131 treatment WBS.
